NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease
NICE approve Saxenda injections (GLP-1 therapy) for people with pre-diabetes who have BMI of at least 35 kg/m2 and high cardiovascular risk. Further details outlined on NICE website: